ABEC Announces $11 Million Investment in a New Manufacturing Facility in North Carolina
14.9.2022 17:11:00 EEST | Business Wire | Press release
ABEC, a global provider of engineered solutions and services for biotech manufacturing, today announced it will invest $11 million to expand single-use disposable container (DC) manufacturing capacity for its CSR biomanufacturing solutions. The company’s project in Wilson, NC includes a 50,000-square-foot facility on 13 acres, which will be outfitted with an ISO-7 cleanroom and state-of-the-art manufacturing equipment. The new facility will be ABEC’s third global DC manufacturing site and is expected to be fully operational in early Q2 2023.
ABEC’s CSR technology is demonstrating significant cost and performance benefits versus other available single-use solutions. ABEC revolutionized single-use processing with large-scale technology and performance across all scales comparable to traditional stirred tank and stainless-steel systems, including the inherent ability to achieve the conditions needed for the latest high-density processes. ABEC is also the only supplier offering complete flexibility in equipment and DC design to optimize productivity, as well as an open-architecture approach to allow for full customer control of their equipment lifecycle and supply chain. This is resulting in broad adoption of CSR across all biopharma industry segments including global multi-nationals, contract development and manufacturing organizations (CDMOs), and small biotech’s.
ABEC’s single-use manufacturing capacity is dedicated to CSR products, and ABEC currently supplies DCs globally from ISO-7 cleanrooms in Fermoy, Ireland, and from its headquarters in Bethlehem, PA USA. The addition of the Wilson, NC facility will ensure ABEC continues to offer the shortest DC lead times in the industry. ABEC plans to create 251 jobs in Wilson County for highly skilled workers such as engineers and manufacturing personnel. ABEC is actively recruiting talent to join the ABEC team for all its facilities including Springfield, MO, and Bethlehem, PA.
“We are pleased that the industry is recognizing the value of our CSR products and we are excited about our investment in Wilson,” said Scott Pickering, ABEC CEO and Chairman. “We look forward to building new long-term partnerships in the area and supporting our customers globally from this new site.”
About ABEC
Since 1974, ABEC has been a global leader in delivering engineered solutions and services for manufacturing in the biotech industry. A majority of the world's pharmaceutical and biotech companies are ABEC customers; with many of today's leading therapies manufactured by processes and equipment engineered, manufactured, installed, and serviced by ABEC. ABEC's unique value is based on long experience, complete in-house capabilities, a customized, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities, ABEC's turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. To learn more about ABEC, visit abec.com, email info@abec.com, and follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005120/en/
Contact information
Media:
Susan Cooper-Curcio
Director of Marketing
+1 (610) 861 4666
scurcio@abec.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa
Cyviz: Microsoft’s Immersive Approach to Collaboration12.6.2026 10:00:00 EEST | Press release
Watch Video Case Study >> This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612831180/en/ Watch Video Case Study >> https://www.cyviz.com/case-studies/microsoft-immersive-suite/ As business and technology environments grow more complex, establishing shared understanding across disciplines has become critical. The Immersive Suite is designed for active collaboration, where visual narratives, data, and technical content are explored interactively. This allows participants to test scenarios, align perspectives, and move more efficiently from discussion to decision. “We deliberately work with familiar tools like PowerPoint. That allows us to focus on storytelling and interaction rather than explaining technology, making collaboration more natural and effective,” says Joris Haverkort, Chief Technology Officer for Microsoft Netherlands. A key principle is simplicity at scale. Instead of relying on specialized tools, users build co
LTM Launches AI 1000 to Develop the Next Generation of Forward Deployed Engineers12.6.2026 09:14:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced AI 1000, a strategic workforce transformation initiative anchored by a dedicated Center of Excellence (CoE). The program will develop a pool of 1,000+ AI-certified engineers, including Forward Deployed Engineers (FDEs), to help enterprises adopt, deploy, and scale AI. The launch comes amid a major shift in enterprise tech talent. The FDE — among the fastest-growing roles in the AI ecosystem — combines the technical knowledge of LLMs and domain SLMs with business understanding to turn ideas into quantifiable ROI accretive outcomes and to drive client adoption. AI 1000 is LTM’s structured response to this shift: it provides the training, platforms, and governed career frameworks to develop FDEs at scale. AI 1000 takes an end-to-end approach to talent development via a four-stage model: Identify, Enable, Deploy, and Govern. It starts by identifying high-potential engineers using a proprietary AI Readi
NTT DATA Group Appoints Kazuhiko Nakayama as New President and Chief Executive Officer12.6.2026 09:00:00 EEST | Press release
NTT DATA Group, a global leader in AI, digital business and technology services, today announces that the Board of Directors has approved the appointment of Kazuhiko Nakayama as NTT DATA Group’s new President and Chief Executive Officer, effective June 12, 2026. Yutaka Sasaki, former President and CEO of NTT DATA Group, will assume the role of Senior Executive Vice President of NTT, Inc., effective June 18. Serving most recently as CFO of NTT DATA Group, Nakayama brings proven leadership and a depth of expertise and experience in defining business strategy and delivering growth. He will continue to strengthen the competitive advantages of the $30+ billion business whilst accelerating it’s AI-centered growth strategy across the 70+ countries and regions in which it operates. NTT DATA Group’s growth strategy will focus on two key areas alongside its core business operations: AI‑empowered New Value & Productivity; and Next‑Generation Infrastructure. It aims to lead in areas such as Operat
Venture Global Announces Closing of $2.25 Billion of Senior Secured Notes12.6.2026 00:00:00 EEST | Press release
Venture Global LNG, Inc. (“Venture Global”) announced today that its wholly-owned subsidiary, Venture Global LNG, Inc. (the “Issuer”) has closed its offering of $1.125 billion aggregate principal amount of its 6.375% senior secured notes due 2034 (the “2034 Notes”) and $1.125 billion aggregate principal amount of its 6.625% senior secured notes due 2036 (the “2036 Notes” and, together with the 2034 Notes, the “Notes”). The Issuer used the gross proceeds from the offering to redeem all of the Issuer’s outstanding 8.125% senior secured notes due 2028 (the “Existing 2028 Notes”) and used cash on hand to pay the redemption premium and related fees and expenses for the offering and the redemption. The 2034 Notes will mature on December 15, 2034, and the 2036 Notes will mature on June 15, 2036. The Notes were issued at par. The Notes will initially not be guaranteed by any of the Issuer’s subsidiaries. In the future, certain of the Issuer’s subsidiaries that incur or guarantee certain amount
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom